Posted by Michael Wonder on 12 Sep 2022
Mersana Therapeutics announces FDA fast track designation granted to XMT-1660 for the treatment of triple negative breast cancer
12 September 2022 - XMT-1660 currently being studied in a Phase 1 trial enrolling patients with breast, endometrial and ovarian cancers.
Mersana Therapeutics today announced that the US FDA has granted fast track designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple negative breast cancer.
